Kornimate/medical-research-clean huggingface dataset:
the stony brook university calm-mom study

Conditions: Pregnancy Related; Stress, Psychological; Anxiety; Perinatal Depression

Summary: the present trial will evaluate the feasibility, acceptability and preliminary efficacy of 2 different internet-delivered programs for prenatal maternal stress. the stress managment and resiliency training program (smart-mom program), an 8-session cognitive behavior therapy (cbt) based mind body program and the mama support program, an 8-session social support group program. sixty pregnant women (\<20 weeks estimated gestational age) will be screened and either enrolled in the online smart mom program or the mama support program. outcomes, including maternal perceived stress, depression, and anxiety will be assessed at post-treatment, three, and six months post program completion. potential impact on infant health outcomes will be assessed via post-delivery electronic medical record review.

aim 1: the investigators will conduct a randomized clinical trial (rct; n=60) to assess the feasibility, acceptability and preliminary efficacy of the stress management and resillency training program (smart pregnancy) delivered online versus a time and attention matched prenatal support group (mama support). it is expected that smart-pregnancy participants will demonstrate high levels of treatment engagement and adherence. it is predicted that participants in the smart-pregnancy condition will demonstrate improvements in emotional distress and stress regulation (as indexed by hair cortisol concentrations) at post-treatment and 3 month follow-up. aim 2: the investigators will conduct a postnatal chart review to explore secondary treatment benefits including pre-and postnatal maternal health and birth outcomes.

Eligibility criteria:
inclusion criteria: * \<21 weeks pregnant with medically confirmed viability * speak, read and write in english fluently, * endorse elevated levels of prenatal maternal stress (pnms; i.e., new prenatal distress questionnaire score \> 19). exclusion criteria: * current enrollment in individual or group psychotherapy * current un-managed serious mental illness including bipolar disorder and psychosis * history of previous suicide attempt * inappropriate for participation in group therapy format as determined by study director

Keywords: prenatal maternal stress perinatal mental health pregnancy perinatal anxiety perinatal depression
early motion following carpal tunnel release

Conditions: Carpal Tunnel Syndrome

Summary: to objectively and subjectively assess two modes of commonly employed rehabilitation and confirm a superior method to treat patients following carpal tunnel release. one of the problems following carpal tunnel release (ctr) for carpal tunnel syndrome, and all hand surgeries, is the debilitation in the postoperative period. this relates to muscle atrophy and joint stiffness due to immobilization or relative inactivity in the postoperative period. specifically, patients suffer increased days off from work, lost wages, and difficulties with activities of daily living affecting the patient and society at large. ctr is a very common procedure in hand surgery making it easy to study and important to optimize the postoperative care.

the surgical procedure, carpal tunnel release, will be performed in a standard open fashion. in a random fashion, the patients will be placed into either of two rehabilitation groups following ctr with specifically different postoperative instructions after the procedure.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of carpal tunnel syndrome * recommended for carpal tunnel release exclusion criteria: * severe thenar weakness * proximal neuropathy of the same arm. * generalized peripheral neuropathy * active psychiatric disorder * chronic renal failure require dialysis * reflex sympathetic dystrophy * previous injury of affected wrist or median nerve * simultaneous ipsilateral upper extremity surgery * carpal tunnel syndrome with acute injury

Keywords: carpal tunnel release rehabilitation early motion
the effect of rehabilitative games with smartpose on upper extremity recovery in stroke patients

Conditions: Stroke, Ischemic; Smartpose; Telerehabilitation

Summary: the goal of this clinical trial is to investigate the effects of smartpose games on upper extremity motor, functional, and sensory recovery in patients with stroke. the main question it aims to answer is: * does the use of rehabilitative games with the smartpose application work to treat upper extremity motor, functional, and sensory recovery in stroke patients? researchers will compare the experimental group with the control group, which receives only conventional exercises with proven effectiveness, to determine whether smartpose has an effect on upper extremity motor, functional, and sensory recovery in stroke patients. the experimental group will receive 30 minutes of neuromuscular therapy and 30 minutes of smartpose, 3 times a week for 8 weeks. the control group will receive 60 minutes of neuromuscular therapy, 3 times a week for 8 weeks.


Eligibility criteria:
inclusion criteria: * mini mental state examination score ≥ 24 * age between 35 and 75 years * medical condition sufficiently stable to allow participation in active rehabilitation * brunnstrom upper extremity stage ≥ 3 * minimum sixth week post-stroke * ability to perform shoulder abduction and flexion against gravity with a minimum of 20° exclusion criteria: * presence of secondary impairments affecting upper extremity movement * modified ashworth scale score of 4 or 5 * inability to maintain independent sitting balance * visual impairment or loss that prevents the perception of visual materials

Keywords: rehabilitation stroke exergaming upper extremity
metabolite biomarkers related to acute rejection in kidney transplantation

Conditions: Kidney Transplantation; Rejection Acute Renal

Summary: the development of acute rejection can only be considered in cases with increasing serum creatinine in patients with kidney transplantation. however, the serum creatinine itself is not specific but also accurate for detection of acute rejection. so the specific biomarker is required for acute rejection of kidney transplant. in this study, the investigators will enroll 200 consecutive kidney transplant patients in seoul national university hospital and follow up. serial collection of urine and serum will be done. acute rejection specific urine metabolite will be found by lc ms/ms.


Eligibility criteria:
inclusion criteria: * kidney transplant patients in seoul national university hospital * patients with triple maintenance immunosuppression including tacrolimus, mycophenolate and steroid exclusion criteria: * history of other organ transplantation * aboi and/or crossmatch(+) transplantation

Keywords: metabolomics biomarker acute rejection
endo-aid assisted tandem colonoscopy rct

Conditions: Colorectal Neoplasms

Summary: this study hypothesizes that more adenomas will be detected using the endo-aid assisted colonoscopy compared to conventional colonoscopy. a single-centre, randomized, same-day, back-to-back tandem colonoscopy trial comparing adenoma missed rate and adenoma detection rate in endo-aid assisted colonoscopy and conventional colonoscopy.

colorectal cancer is the third common cancer in the world and the commonest cancer in hong kong. most sporadic colorectal cancers arise from benign polyps via adenoma-carcinoma sequence or the serrated polyp-carcinoma sequence. there are reports of unexpectedly high risk of interval carcinomas, as high as up to 9%, raising concerns about the effectiveness of colonoscopy in preventing colorectal cancers. different techniques have been described to improve the area of mucosa visualised but lesions may still be missed due to failure of identification by the endoscopist. computer aided diagnosis (cad) assisted colonoscopy is becoming increasingly popular to address human error. deep learning technology has surpassed human learning and advancement in technology now allows real-time artificial intelligence to assist colonoscopists in polyp detection.

Eligibility criteria:
inclusion criteria: * patients aged 18years or above * referred to endoscopy unit for diagnostic or surveillance colonoscopy exclusion criteria: * familial history of familial adenomatous polyposis / hereditary non-polyposis colorectal cancer * known history of inflammatory bowel disease * known colitis or suspicion of colitis (inflammatory bowel disease, diverticulitis, infective colitis) * emergency endoscopy of any nature (eg gastrointestinal bleeding, colonic decompression) * previous incomplete colonoscopy (not including insufficient preparation) / difficult colonoscopy * patients referred for a therapeutic procedure or assessment of a known non-resected lesion * patients with known palliative colorectal malignancy * patient with coagulopathy * patient with colostomy * patient with multiple co-morbidities (american society of anaesthesiologist \>3) * inability to give informed consent

Keywords: computer aided polyp detection colonoscopy polyp detection colorectal polyps colorectal cancer
ketamine-propofol versus ketamine alone for procedural sedation in adults

Conditions: Fracture; Dislocation

Summary: using ketamine for procedural sedation in adults is often uncomfortable for emergency physicians because of the significant proportion of patients experimenting recovery agitation. the investigators believe that combining propofol to ketamine, the proportion of recovery agitation will be significantly lowered. the objectives of this double-blinded, randomized controlled trial are to compare the proportion of recovery agitation in adults receiving procedural sedation with ketamine-propofol versus ketamine alone, and to compare the proportion of other classical procedural sedation side-effects and parameters such as respiratory depression, hypotension, sedation duration, time of recovery, procedural failures, and levels of satisfaction.


Eligibility criteria:
inclusion criteria: * 18 years and older * indication of procedural sedation exclusion criteria: * allergy to propofol or ketamine * alcohol or drug intoxication * altered mental status * asa physical status score \> 2 * hemodynamic unstability

Keywords: procedural sedation ketamine-propofol ketamine
immune benefits of consumption of dairy yogurt in elderly

Conditions: Immune Deficiency

Summary: to investigate the impact of consuming dairy yogurt on immun function including natural killer (nk) cell activity, circulating levels of cytokines, and immunoglobulin (ig) in elderly.

a randomized, open-labelled, placebo-controlled study was conducted on 200 nondiabetic, nonobese and elderly (≥60 years) subjects. over a twelve-week period, the test group consumed one bottle (120 ml) of dairy yogurt each day, whereas the placebo group consumed same volume of low fat milk daily. nk cell activity (%) was measured based on the ratios of effector cells (e; peripheral blood mononuclear cells, pbmcs) from each participant to target cells (t; k562 cells) at e:t= 10:1, 5:1, 2.5:1, 1.25:1 or 0.625:1. in addition, cytokines and immunoglobulin levels measured using commercial kits as manufacturer's instruction.

Eligibility criteria:
inclusion criteria: * able to give informed consent * over 60 years old without any health problems * the levels of white blood cells within range 4x10\^3/μl\~10x10\^3/μl exclusion criteria: * individuals who get a cold * diabetes * hypersensitivity or disease history for milk protein * epilepsy, neurological, or psychological disease * alcoholism or drug addiction * liver disease or severe kidney failure disease * inflammation-related disease * consumption of other test products or drugs within 1 month prior to screening * regular consumption of immune-related functional foods including yogurt or milk within 1 month prior to screening * history of inflammation-related disease or taking medication to treat inflammation-related disease within 1 month prior to screening * history of cancer within 5 years * any inappropriate condition

Keywords: probiotics immune function natural killer cell activity interleukin-12 interferon-gamma immunoglobulin
patient-derived organoids predicts the clinical efficiency of colorectal liver metastasis

Conditions: Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases

Summary: accumulating evidence indicates that patient- derived organoids (pdos) can predict drug responses in the clinic. metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. tumor heterogeneity is the cause of treatment failure. in this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.


Eligibility criteria:
inclusion criteria: * histologically proven colorectal cancer with liver metastasis * aged between 18 and 70 years * written informed and signed consent * accessible to surgery sample of metastasis and primary tumor exclusion criteria: * less than 18 years and older than 70 years * not able to give informed consent * not accessible to surgery sample
air tamponade and non-supine positioning in macular hole surgery.

Conditions: Macular Holes

Summary: this is a prospective, multicenter, randomized non-inferiority trial, where the macular hole closure rate with intraocular air tamponade is compared to the closure rate with gas tamponade.the patients are randomized to receive either air or gas (26% sf6) as intraocular tamponade, just prior to the intraocular flushing of the tamponade during the vitrectomy procedure. postoperatively, the patients adhere to the nonsupine regimen for three days, and the tennis ball technique is used during sleep to enhance patients' positioning compliance.


Eligibility criteria:
inclusion criteria: * primary macular hole ≤ 400 μm * duration no more than 24 months * able to sign informed content * signed informed content exclusion criteria: * earlier vitreoretinal surgery in present eye * secondary macular holes caused by other conditions than vitreomacular traction * myopic macular hole, i.e. excessive myopia (more than -6 dioptres) * posttraumatic macular hole * macular holes secondary to retinal detachment or other retinal diseases * surgery under general anesthesia * visual acuity below 20/40 in fellow-eye
combination chemotherapy in treating patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy in treating patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: * determine the response rate and duration of response to mitomycin, vinorelbine, and cisplatin plus tretinoin in patients with stage iiib or iv non-small cell lung cancer. * determine the toxicity of this treatment regimen in these patients. * determine survival of these patients with this treatment regimen. outline: patients receive tretinoin orally twice daily for 4 days starting days 1 and 8; cisplatin iv over 2 hours and vinorelbine iv on days 1 and 8; and mitomycin iv (courses 1 and 3) on day 1. treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. patients are followed for survival. projected accrual: at total of 15-46 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed stage iiib or iv non-small cell lung cancer * measurable disease * no brain metastases patient characteristics: age: * over 18 performance status: * zubrod 0-2 life expectancy: * not specified hematopoietic: * absolute granulocyte count greater than 2,000/mm\^3 * platelet count greater than 100,000/mm\^3 hepatic: * bilirubin less than 2 times upper limit of normal (uln) * ast and alt less than 2.5 times uln (unless attributed to liver metastases) renal: * creatinine no greater than 1.5 mg/dl and/or * creatinine clearance at least 60 ml/min cardiovascular: * no myocardial infarction within past 6 months * no congestive heart failure * no uncontrolled arrhythmia other: * no other concurrent or prior malignancy within past 5 years except localized basal cell or squamous cell skin cancer * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * hiv negative prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy endocrine therapy: * not specified radiotherapy: * at least 4 weeks since prior radiotherapy with clearly progressive disease * concurrent palliative radiotherapy allowed if no evidence of disease progression surgery: * not specified

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
capillary and venous accuracy: lifescan products vs hospital reference and ysi

Conditions: Diabetes Mellitus

Summary: this study is to evaluate accuracy between product platforms in the hands of users, comparing capillary to venous response vs ysi reference instrument as well as the local hospital analyser.

this study will gather data to: * determine if extreme bias can be observed between 3 candidate products for user accuracy. * assess the offset between venous blood samples versus capillary blood samples. * determine if there are measurable donor factors which influence the product bias. * assess any offset between ysi 2300 reference instruments and hospital laboratory analyser and impact on bias difference between bgm product types.

Eligibility criteria:
summary of inclusion criteria: * male or female subjects with t1dm or t2dm. * must be able to read and sign the approved consent form. * registered into the lifescan patient registry. * currently performing self monitoring of blood glucose ( smbg) summary of exclusion criteria: * conflict of interest - prospective participants will be excluded from enrollment if they are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets the type of products tested under the scope of this procedure.
role of soy supplementation in prostate cancer development

Conditions: Prostate Neoplasm

Summary: this is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. patient will be randomized it either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. patient's blood and prostate tissue will be evaluated to determine the effects of the soy supplement on the prostate tissue.

this is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. patients will be randomized to either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. the specific objectives are: 1. to assess the effect of soy supplementation on endogenous hormone production levels and serum prostate specific antigens. 2. to assess the impact of soy supplementation on estrogen receptor expression(er). 3. to determine the impact of soy isoflavones on cell cycle regulation and associated gene expression.

Eligibility criteria:
inclusion criteria: * histologically proven prostate cancer. * surgical candidate for prostatectomy. * during study period, must agree not to take new supplements. * no concurrent chemotherapy, radiation or hormonal therapy. * no history of prior allergy to soy based products. * must not have been taking soy supplements or soy isoflavones within 90 days prior to study enrollment. * must be able to safely be on study supplements for period of at least two weeks prior to scheduled prostatectomy. * must give written and informed consent in accordance with institutional and federal guidelines. exclusion criteria: during study period, must agree not to take new supplements. * no concurrent chemotherapy, radiation or hormonal therapy. * no history of prior allergy to soy based products. * must not have been taking soy supplements or soy isoflavones within 90 days prior to study enrollment. * must be able to safely be on study supplements for period of at least two weeks prior to scheduled

Keywords: estrogen receptor isoflavones prostate neoplasm soy supplementation
study of n-acetylcysteine in acute liver failure (alf)

Conditions: Acute Liver Failure; Fulminant Hepatic Failure

Summary: this proposed study is a multi-center open label study to determine if n-acetylcysteine has any survival benefits in patients with acute liver failure.

patients admitted to study sites with carefully defined criteria for acute liver failure and who are thought not to have acetaminophen toxicity, mushroom poisoning, pregnancy-related liver failure, or malignancy will be eligible. each patient will receive intravenously in solution of 5% dextrose in water containing n-acetylcysteine, beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, and in declining doses over a total of 72 hours. care of patients and consideration of transplantation or other clinical decisions will not be affected by the study or the use of study drug.

Eligibility criteria:
inclusion criteria: * written informed consent from patient's next of kin * altered mentation of any degree (encephalopathy) * evidence of moderately severe clotting abnormalities (international normalized ratio ≥ 1.5) * a presumed acute illness onset of less than 26 weeks * admitted to study site hospital intensive care units with acute liver failure and who can be evaluated and started on treatment within the first 24 hours of hospitalization * all subjects will be between 18 and 70 years * the nih guidelines on the inclusion of women and minorities as subjects will be observed exclusion criteria: * patients less than age 18 or over 70 years of age * acetaminophen or mushroom poisoning induced liver failure * patients with a diagnosis of shock liver (ischemic hepatopathy) * acute liver failure of pregnancy * acute liver failure thought secondary to intra-hepatic malignancy * cerebral herniation * intractable arterial hypotension * severe sepsis (temperature \>39º c and/or significant bacteremia) present at the time of enrollment

Keywords: liver disease
jedi grip versus double operator technique for ultrasound guided infraclavicular block

Conditions: Ultrasound; Nerve Block

Summary: the investigators aimed to compare the block characteristics of the single operator "jedi grip" technique and the conventional double operator technique.

patients undergoing hand, wrist, elbow and forearm surgery randomly assigned two groups (group i: jedi grip and group ii: conventional double operator technique). by a blind observer, the block characteristics were evaluated and recorded .

Eligibility criteria:
inclusion criteria: * undergoing elective hand, wrist and forearm surgery exclusion criteria: * hepatic or renal failure * serious cardiac or pulmoner disease * local or systemic infection * sepsis * coagulation disorder * neurological, muscular or psychiatric disease * body mass index (bmi) below 18.5 or above 35 * drug and substance abuse * pregnancy * refusal of regional anesthesia * history of allergy to local anesthetics * mental-motor retardation (inability to consent or assess the visual analog scale(vas) pain score) * preoperative long-term nsaids or opioid use.

Keywords: jedi grip ultrasound guided infraclavicular block